Scientists at the National Institutes of Health (NIH) have engineered an innovative artificial intelligence (AI) system aimed at optimizing the matching of prospective trial participants with appropriate clinical research studies listed on ClinicalTrials.gov. A paper in Nature Communications highlights the […]
AI System by NIH Enhances Patient Matching for Clinical Trials Read More »
TAHO Pharmaceuticals Ltd. has begun administering doses to participants in its phase III trial in the US for its leading product, TAH3311, a pioneering antithrombotic oral dissolving film (ODF). In July 2023, their proposal for a 505(b)(2) NDA submission, which
TAHO Pharma Initiates Dosing in US Phase III Study of Antithrombotic Oral Film, TAH3311 Read More »
Cytokinetics, a specialty biopharmaceutical company focusing on cardiovascular diseases in advanced stages, has joined forces with Bayer through an exclusive collaboration and licensing arrangement. This partnership aims to advance the development and marketing of aficamten for patients in Japan suffering
Cytokinetics and Bayer Partner for Aficamten Development and Commercialization in Japan Read More »
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for the drug sparsentan, also known as Filspari, for the treatment of primary immunoglobulin A nephropathy (IgAN). Renowned as IgA nephropathy or Berger’s disease, this kidney disorder arises
UK MHRA Approves Sparsentan for Treating Primary IgA Nephropathy in Adults Read More »
Abbott, a leader in the healthcare sector, revealed significant new findings concerning its Amplatzer Amulet Left Atrial Appendage (LAA) Occluder for individuals with atrial fibrillation (AFib) who face heightened stroke risk. Recent five-year research highlights that patients using Abbott’s Amplatzer
Biosion, Inc. (Biosion), a global biotechnology company in the R&D phase, unveiled a new exclusive licensing deal with Aclaris Therapeutics. This agreement grants Biosion universal rights (excluding Greater China) for BSI-045B, a potential pioneering, clinical-stage, innovative anti-TSLP monoclonal antibody, in
AVPN, recognized as Asia’s leading social investment network, has introduced the ‘Climate x Health: Lighthouse for Asia’ initiative with support from the Bayer Foundation. The US$ 5 million fund was unveiled at the Singapore Pavilion during COP29 in Baku, Azerbaijan.
**Endo’s Expansion on Clonazepam Tablet Recall Over Potential Packaging Mislabeling** Endo, Inc., a multifaceted pharmaceutical corporation, has communicated that its subsidiary, Endo USA, Inc., will be broadening the initial voluntary recall of clonazepam orally disintegrating tablets, USP (C-IV). This decision
The Telangana government has reported remarkable strides in the life sciences sector, successfully securing over Rs. 36,000 crore in investments from more than 140 initiatives in the past year. These investments are poised to create 51,000 direct employment opportunities and
GSK plc has unveiled encouraging top-line results from the GLISTEN trial, an expansive Phase III clinical study investigating the efficacy of linerixibat, a novel targeted inhibitor of the ileal bile acid transporter (IBAT), in treating adults suffering from cholestatic pruritus